Assignee
SANTARIS PHARMA AS
13 granted patents·18 pending applications·1,207 citations·filing 2001–2015
Top patents by PatentIndex Score
31 records- 0198US7589190B2Potent LNA oligonucleotides for the inhibition of HIF-1A expressionSANTARIS PHARMA AS·Filed 2005·Granted Sep 15, 2009·129 cites·8 claims
- 0297US9428534B2Antisense designSANTARIS PHARMA AS·Filed 2013·Granted Aug 30, 2016·46 cites·78 claims
- 0397US7687617B2Oligonucleotides with alternating segments of locked and non-locked nucleotidesSANTARIS PHARMA AS·Filed 2003·Granted Mar 30, 2010·207 cites·26 claims
- 0496US7569575B2Synthesis of locked nucleic acid derivativesSANTARIS PHARMA AS·Filed 2003·Granted Aug 4, 2009·282 cites·8 claims
- 0594US7622453B2Oligomeric compounds for the modulation of Bcl-2SANTARIS PHARMA AS·Filed 2004·Granted Nov 24, 2009·114 cites·57 claims
- 0692US6998484B2Synthesis of purine locked nucleic acid analoguesSANTARIS PHARMA AS·Filed 2001·Granted Feb 14, 2006·259 cites·51 claims
- 0791US8361980B2Pharmaceutical compositions for treatment of microRNA related diseasesSANTARIS PHARMA AS·Filed 2009·Granted Jan 29, 2013·40 cites·31 claims
- 0891US7153954B2Method for preparation of LNA phosphoramiditesSANTARIS PHARMA AS·Filed 2002·Granted Dec 26, 2006·111 cites·7 claims
- 0987US8026355B2Oligomeric compounds for the modulation of survivin expressionSANTARIS PHARMA AS·Filed 2010·Granted Sep 27, 2011·10 cites·9 claims
- 1082US9133455B2Pharmaceutical composition comprising anti-miRNA antisense oligonucleotidesSANTARIS PHARMA AS·Filed 2014·Granted Sep 15, 2015·4 cites·21 claims
- 1175US9447138B2Potent LNA oligonucleotides for the inhibition of HIF-1a expressionSANTARIS PHARMA AS·Filed 2013·Granted Sep 20, 2016·1 cites·4 claims
- 1275US9297010B2Short interfering RNA (siRNA) analoguesSANTARIS PHARMA AS·Filed 2014·Granted Mar 29, 2016·2 cites·30 claims
- 1370US2014128591A1Antisense designSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 1468US6858726B2Synthesis of allofuranoseSANTARIS PHARMA AS·Filed 2002·Granted Feb 22, 2005·2 cites·16 claims
- 1568US2014194614A1Amino-lna, thio-lna and alpha-l-oxy-lnSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 1666US2014128586A1Amino-lna, thio-lna and alpha-l-oxy-lnSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 1764US2009005335A1Compounds for the modulation of beta-catenin expressionSANTARIS PHARMA AS·Filed 2008·Application pending·0 cites
- 1862US2009264353A1Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of DiseaseSANTARIS PHARMA AS·Filed 2007·Application pending·0 cites
- 1961US2010004320A1Pharmaceutical CompositionSANTARIS PHARMA AS·Filed 2007·Application pending·0 cites
- 2059US2014357849A1Splice switching oligomers for tnf superfamily receptors and their use in treatment of diseaseSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 2158US2014031409A1Methods for treating androgen receptor dependent disorders including cancersSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 2250US2006154888A1LNA oligonucleotides and the treatment of cancerSANTARIS PHARMA AS·Filed 2005·Application pending·0 cites
- 2349US2004248840A1Oligomeric compounds for the modulation of ras expressionSANTARIS PHARMA AS·Filed 2004·Application pending·0 cites
- 2449US2010323967A1RNA Antagonist Compounds for the Modulation of MCL-1SANTARIS PHARMA AS·Filed 2008·Application pending·0 cites
- 2546US2004241717A1Oligomeric compounds for the modulation of thioredoxin expressionSANTARIS PHARMA AS·Filed 2004·Application pending·0 cites
- 2643US2014343127A1Compounds for the modulation of smn2 splicingSANTARIS PHARMA AS·Filed 2012·Application pending·0 cites
- 2742US2010062994A1Adenosine Receptor AntagonistsSANTARIS PHARMA AS·Filed 2007·Application pending·0 cites
- 2842US2015315595A1Compositions and Methods for Modulation of ATXN3 ExpressionSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 2942US2008249039A1Modified Short Interfering Rna (Modified Sirna)SANTARIS PHARMA AS·Filed 2005·Application pending·0 cites
- 3040US2014323557A1Compounds for the modulation of beta-catenin expression and uses thereofSANTARIS PHARMA AS·Filed 2012·Application pending·0 cites
- 3138US2015252371A1Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of DiseaseSANTARIS PHARMA AS·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SANTARIS PHARMA AS files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →